Document:

EX-10.8

 EXHIBIT 10.8 

SERVICE AGREEMENT 
 This service agreement
(the “Agreement”), made and entered into as of 28 December 2014 (the “Effective Date”), by and between: 
 Cardio3 Biosciences SA,
with its principal place of business at Rue Edouard Belin 12, B-1435 Mon-Saint-Guibert, Belgium (“C3BS”), duly represented by Mr Patrick Jeanmart, Chief Finance Officer, 

and 
 ViaNova SPRL, with its principal place of business at 1380
Lasne, Rue du Chêne au Corbeau 54, represented by Vincent Brichard, Managing Director (“CONSULTANT”), 
 Each a “Party”, and
collectively the “Parties”. 
 The Agreement shall enter into force on the Effective Date. 

WHEREAS 
 C3BS is developing novel cell therapies in
cardiovascular and oncology fields. Within the scope of the research and development programs, C3BS shall select suitable consultant which will help C3BS developing its product pipeline towards commercialization. 

C3BS desires to retain the services of CONSULTANT from the Effective Date of this Agreement. 

The CONSULTANT holds expertise in the field of oncology in research and development, regulatory, medical affairs and central commercial programs. 

The CONSULTANT is willing to be retained by C3BS on the terms and subject to the conditions set forth in this Agreement. 

Now therefore, the Parties agree as follows: 
 Article 1
Services 
  

	1.1	Description of Services. 

 As of the Effective Date, and as requested by C3BS, CONSULTANT shall perform
the services as set forth on Schedule 1 (the “Services”) within the Territory (as that term is defined in Section 2.2 below). 
  

	1.2	Performance of Services. 

 All Services shall be performed by CONSULTANT as per the Effective date. 

  
 Page 1 of 10 

 Article 2 Definitions 
  

	2.1	Confidential Information. 

 Confidential Information is all information related to any aspect of the
business of C3BS which Is either information not known by actual or potential competitors of C3BS or is proprietary information of C3BS, whether of a technical nature or otherwise. Confidential Information includes, without limitation, any
inventions, disclosures, processes, systems, methods, formulae, devices, patents, patent applications, trademarks, intellectual properties, instruments, materials, products, patterns, compilations, programs, techniques, sequences, designs, research
or development activities and plans, specifications, computer programs, source codes, mask works, costs of production, prices or other financial data, volume of sales, promotional methods, marketing plans, lists of names or classes of customers or
personnel, lists of suppliers, business plans, business opportunities, or financial statements. 
  

	2.2	Territory. 

 Territory means worldwide. 

Article 3 Term, termination and stepdown 
  

	3.1	Term/Termination. 

 The term of this Agreement shall commence on the Effective Date and shall continue
until twelve (12) months from the Effective Date (the “Expiry Date”). It is provided however, that either CONSULTANT or C3BS may terminate this Agreement by written notice to the other party, in accordance with Section 3.2, 3.3
or 3.4 below. After the Expiry Date, the parties may renew this Agreement by written mutual consent. 
  

	3.2	Termination by C3BS. 

 C3BS is entitled to terminate this Agreement at any time before the Expiry Date
with three (3) months notice. C3BS is entitled to terminate this Agreement at any time before the Expiry Date without notice for any of the following reasons: 
  

	(i)	a fault, negligence or breach of contract by CONSULTANT and which CONSULTANT has not cured within fifteen (15) days of the notice sent by C3BS asking CONSULTANT to cure it, 

 

	(ii)	the inability of CONSULTANT to provide the Services for two (2) subsequent months no matter for what reason and including if this is due to a force majeure event, or 

 

	(iii)	in case of conflict of interest as described under article 5.1 hereunder. 

  

	3.3	Termination by CONSULTANT. 

 In the event CONSULTANT elects to terminate this Agreement prior to the
Expiry Date, C3BS may request that CONSULTANT continue to provide the Services of the Designated Consultant for a one (1)-month period following CONSULTANT’S notice of its election to terminate this Agreement. If C3BS fails to request such a
continuation of the Agreement, this Agreement shall terminate as of C3BS’s receipt of CONSULTANT’s written notice of termination, and C3BS’s obligations to pay CONSULTANT for further Services shall cease as of the time of termination.

  
 Page 2 of 10 

	3.4	Remaining Payments. 

 Within thirty (30) days after termination of this Agreement for any reason,
CONSULTANT shall submit to C3BS an itemized invoice for any fees or expenses incurred in accordance with SCHEDULE 2 hereof and C3BS shall make payment to CONSULTANT within thirty (30) days after receipt of such itemized invoice, subject to
verification by C3BS that such fees and expenses were reasonably incurred in furtherance of this Agreement. 
  

	3.5	Termination’s effect. 

 Upon termination of this Agreement for whatsoever cause, CONSULTANT and Its
employees shall immediately stop providing the Services unless otherwise requested by C3BS, and they shall deliver to C3BS or any person designated by this latter all materials, documents, data or anything else which was provided by C3BS in
connection with and for the purpose of the provision of the Services or which was developed by CONSULTANT and its employees in the performance of the Services. 

Article 4 Compensation 
  

	4.1	Fees. 

 In consideration of the Services actually performed by CONSULTANT, CONSULTANT shall be entitled
to compensation as more fully described on SCHEDULE 2 hereto. The same principle will apply for expenses supported by CONSULTANT on behalf of C3BS, Fees and expenses will be reported by consultants to C3BS based on timesheets and expenses notes on a
monthly basis. Once approved, services and expenses will be paid with thirty (30) working days. 
  

	4.2	Taxes. 

 CONSULTANT acknowledges and agrees that any amount received under this Agreement is gross of any
taxes/fees and levies of any nature whatsoever which may be Imposed by any authority with jurisdiction over any amounts received by CONSULTANT under this Agreement with the exception of Value Added Tax (VAT) “Taxe sur la Valeur Ajoutée
(TVA)/ Belasting op Toegevoegde Waarde (BTW)” as required under Belgian legislation. CONSULTANT shall be solely responsible for the payment of any and all such other taxes, fees and levies. 

Article 5 Independent contractor and other matters 
  

	5.1	Independent Contractor. 

 It is understood that CONSULTANT is being retained and has contracted with C3BS
only for the purposes and to the extent set forth In this Agreement, and its relationship to C3BS and any of its subsidiary companies shall, during the period of the retainer and service, be that of an independent contractor, and CONSULTANT shall be
free to render services to such other persons, firms, or corporations as CONSULTANT deems advisable so long as such services do not create a conflict of interest between C3BS and such other persons, firms, or corporations. 

 

	5.2	Conflicts. 

 In the event that a possible conflict of interest for the defined scope of SERVICES arises
at any time during the term of the Agreement between the interests of C3BS and those of other clients of CONSULTANT, CONSULTANT agrees to notify C3BS thereof promptly. C3BS will have the right to decide whether CONSULTANT can or not be in such
situation of conflict of interests, in 

  
 Page 3 of 10 

 
case C3BS agrees CONSULTANT to be in such situation, C3BS’s decision will remain valid until the end of the current agreement. In case C3BS refuses CONSULTANT to be in such situation of
conflict of interests, then C3BS will inform CONSULTANT and CONSULTANT will have a ten (10) working days period to take appropriate measures, after which C3BS will have the right to terminate the agreement with immediate effect and without
liability nor payment of the Termination Compensation The fact that CONSULTANT has informal contacts with a third party that could result in a conflict of interest situation will not be taken Into account. However it is CONSULTANT’S
responsibility to inform C3BS of any such tangible discussion. 
  

	5.3	CONSULTANT’s Employees and partners. 

 No person providing Services on behalf of CONSULTANT
hereunder shall be considered under the provisions of this Agreement or otherwise, as having status as an employee of C3BS, nor shall they be entitled hereafter to participate in any plans, arrangements, or distributions by C3BS relating to any
pension, deferred compensation, bonds, stock bonus, stock option, hospitalization, insurance, or other benefits extended to its employees since such individuals are employees of CONSULTANT, except as specifically provided for in this Agreement. 

 

	5.4	Labor law and insurance. 

 CONSULTANT shall at its sole cost and expenses take out and maintain insurance
with an insurance company as will provide full and adequate protection against all claims of CONSULTANT’S personnel including those concerning on or off-the-job death, injuries or disabilities. 

Article 6 Confidentiality and intellectual property 
  

	6.1	Confidentiality. 

 CONSULTANT, and all of its employees, shall, both during and subsequent to providing
Services as described herein, keep all Confidential Information in confidence, including knowledge of C3BS’s projects and general activities and any information not publicly disclosed relating to C3BS’s business which CONSULTANT, its
employees or subcontractors may acquire through Its consulting activities or otherwise, either before or during the term of this Agreement. CONSULTANT, its employees or its subcontractors, will not disclose such information in any manner without the
express written permission of C3BS; title to all property Involved shall remain exclusively in C3BS. It is understood that this Agreement will not be deemed breached if disclosure occurs inadvertently during a collaborative scientific effort but
CONSULTANT and any of its employees will use their best efforts to avoid such disclosure. Upon termination of Services, or upon request at any time, CONSULTANT shall account for and return to C3BS all papers containing any such Confidential
Information/In addition, CONSULTANT and its employees shall not disclose or otherwise transfer to C3BS any confidential information of third party, which they may have acquired as a result of any previous or future employment or consulting
relationship. 
 CONSULTANT represents on behalf of itself and each of its employees who will be rendering Services pursuant hereto, that its and their
performance of all the terms of this Agreement and its retention as a consultant by C3BS does not and will not breach any agreement to keep In confidence confidential information acquired by CONSULTANT or such employees in confidence or in trust
prior to its retention as a consultant by C3BS. 

  
 Page 4 of 10 

	6.2	Ownership. 

 All materials, reports, data submitted to or developed for C3BS during the term of this
Agreement and paid for by C3BS, will be our C3BS’s sole property. Therefore, C3BS shall have the right, without further payment over and above that set forth in SCHEDULE 2 ‘Fees’, forever to use and dispose fully any and all
information disclosed or developed by CONSULTANT in the performance of the Services for C3BS. Any use of such materials, reports or data by CONSULTANT for any other purpose than the Services performance must then be approved in writing by C3BS in
advance. 
  

	6.3	Inventions and discovery. 

 All rights to any discovery or invention conceived or conceived and reduced
to practice in the direct performance of the Services conducted under the Agreement shall belong to C3BS. CONSULTANT and its employees agree to assign to C3BS, at Its request, the sole and exclusive ownership thereto, upon the payment of costs by
C3BS, If any, incurred by CONSULTANT and its employees in the filing, prosecution, or maintenance of any patent application or patent issuing thereon. Such application, if any, shall be filed and prosecuted by C3BS. CONSULTANT and its employees
shall promptly disclose to C3BS any invention or discovery arising under the Agreement. 
 Article 7 Conflict of interest and exclusivity 

CONSULTANT confirms that he has advised C3BS in writing prior to the date of signing this Agreement of any relationship with third parties, including
competitors of C3BS, which would present a conflict of interest with the rendering of the SERVICES, or which would prevent CONSULTANT from carrying out the terms of this Agreement or which would present a significant opportunity for the disclosure
of confidential information. CONSULTANT will advise C3BS of any such relationships that arise during the term of this Agreement. C3BS will then have the option either to terminate this Agreement without further liability to CONSULTANT, except to pay
for SERVICES actually rendered or to prevent CONSULTANT to enter is such relationship. 
 Article 8 Non Exclusivity and Exclusion of Advice for competing
assets owned by third parties. 
 It is agreed that CONSULTANT, for the duration of this agreement, put his services not exclusively at the disposal of
C3BS. This means that during the term of this Agreement, CONSULTANT can seek, accept or perform any services without the specific and written approval of C3BS. However, any consulting or other services or relationship with third parties for which
the support of CONSULTANT is required and that would present conflict of interest with the rendering SERVICES for C3BS, should be reported to C3BS and will be handled as described in Article 7 ‘Conflict of interest’. 

Article 9 Miscellaneous 
  

	9.1	Force Majeure. 

 No party shall not be liable to the other party for any failure or delay caused by
events beyond control, including, without limitation, the other party’s failure to furnish necessary information; sabotage, failure, or delays in transportation or communication; failures or substitutions of equipment; labour disputes;
accidents; fuel, raw materials, or equipment; or technical failures. 

  
 Page 5 of 10 

	9.2	Governing Law. 

 This Agreement shall be governed and construed in all respects in accordance with the
laws of Belgium as they apply to a contract entered into and performed in that Belgium. 
  

	9.3	Arbitration. 

 Any dispute or litigation relating to the existence, conclusion, validity, interpretation
or performance of this Agreement shall be finally settled in accordance with the Commercial Arbitration Rules of Belgium then in effect, by one or more arbitrators appointed in accordance with these rules. The place of arbitration shall be Brussels,
Belgium, and the language of the proceeding shall be French. 
  

	9.4	Waiver and Survival. 

 The waiver of the breach of any provision of this Agreement shall not operate or
be construed as a waiver of any subsequent breach of the same or other provision hereof. The provisions of Article 6 of this Agreement shall survive any termination of this Agreement for a period of one (1) year following the termination date.

  

	9.5	Notices. 

 All notices and other communications under this Agreement shall be in writing. Unless and
until CONSULTANT is notified in writing to the contrary, all notices, communications and documents directed to C3BS and related to the Agreement, if not delivered by hand, shall be mailed and addressed as follows: 

ViaNova SPRL 
 Rue du Chêne
au Corbeau 54 
 B-1380 Lasne 
 Unless and
until CONSULTANT is notified in writing to the contrary, all notices, communications and documents intended for CONSULTANT and related to this Agreement, if not delivered by hand, shall be mailed and addressed as follows: 

Cardio3 Biosciences SA 
 Rue
Edouard Belin 12 
 B-1435 Mont Saint Guibert 

Attention: Christian HOMSY 
 Notices and
communications shall be mailed by registered or certified mail, return receipt requested, postage prepaid. Email with acknowledgment of receipt will be accepted by both parties. All notices related to this Agreement shall be deemed received upon
delivery or, If mailed, within three (3) days after mailing in accordance with this section 9.5. 

  
 Page 6 of 10 

	9.6	Name. 

 The term, C3BS, as used herein, shall include any subsidiary or affiliate or branch of C3BS. In
performing its duties, CONSULTANT may request from C3BS the ability to utilize any trade names, trademarks or other branding marks or information of C3BS that might be helpful in completing the Services described in the schedule 1. 

 

	9.7	Assignment. 

 This Agreement shall be binding upon CONSULTANT, its successors and assigns, and shall
inure to the benefit of C3BS, its successors and assigns. 
  

	9.8	Attorneys Fees. 

 If any party seeks to enforce its rights under this Agreement by legal proceedings or
otherwise, the non-prevailing party shall pay all costs and expenses of the prevailing party, 
  

	9.9	Counterparts. 

 This Agreement may be executed in one or more counterparts, all of which taken together
shall constitute one and the same Agreement. 
  

	9.10	Sole Agreement and Enforcement. 

 This Agreement including all its Schedules, which are an integral part
thereof, embodies the entire undertaking of the parties and there are no promises, terms, conditions or obligations oral or written other than those contained in this Agreement. If any provision of this Agreement shall be declared invalid, illegal
or unenforceable, such portion shall be severed and all remaining portions shall continue in full force and effect. 
 IN WITNESS WHEREOF, 

The parties have caused this Agreement to be executed by their duly authorized representatives. 

 

									
	Cardio3 Biosciences SA				ViaNova SPRL
					
	By:		 /s/ Christian Homsy
				By:		  

	Christian Homsy, Chief Executive Officer				
					
	Date:		 30/01/2015
				Date:		  

  
 Page 7 of 10 

 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 Page 8 of 10 

 SCHEDULE 1 

DESCRIPTION OF THE SERVICES 
 The role of the
CONSULTANT Is the one of a “Vice-President Immuno-Oncology” aimed at helping the CEO and the Board on the constructive challenge on both the projects content and the organizational aspects and the general performance to optimize the value
of the assets. It is understood that the primary operational responsibilities will remain with the department heads, the CONSULTANT acting mostly as an advisor. 

The Job description includes developing proposals in strategy, the development of entrepreneurial leadership, the scrutiny of performance in meeting agreed
goals and objectives and the monitoring of the performance reports, assessing the integrity of information. 
 The scope of activities includes preclinical
activities, clinical development plans, communication planning and preliminary commercial assessment of the assets. 
 The ultimate objective is to maximize
the value of the company on a financial risk-based evaluation of the various assets in the field of immuno-oncology developed by C3BS, namely CAR T-cells expressing NKG2D or NKp30 or B7H6 target, or the T3 allogeneic program. 

Note: the title may change as a transition to the Board of Directors may be contemplated with a scope of activities encompassing a broader view on all
projects at C3BS. 

  
 Page 9 of 10 

 SCHEDULE 2 

FEES 
  

	 	1.	CONSULTANT will invoice C3BS on a monthly basis. The invoice will be supported by a detailed timesheet and CONSULTANT will only invoice the time spent on the project. 

 

	 	2.	Services rendered by CONSULTANT will be charged at a daily rate of 2.000 € or an hourly rate of 250€. 

  

	 	3.	These fees are valid through the Term of the agreement. At the beginning of each year thereafter, fees could be subject to adjustment by up to 3%, based on the rate of inflation. 

 

	 	4.	At signature of the Agreement, the CONSULTANT will be entitled to 10.000 warrants of C3BS, at the conditions set by the Board of Directors. A third of these warrants will be vested at the end of the first, second and
third year of services initiation. 

  

	 	5.	Incentives: an incentive scheme, reflecting the optimization of the valuation of the assets will be determined by the CONSULTANT and C3BS within the month following the start of this agreement. 

 

	 	6.	Travel Expense Guidelines done exclusively for the related SERVICES: 

  

	 	a.	For flights, travel guidelines are to use flexible economy airfare rates (economy!) in Europe, and business rates to travel to the US or Asia. For train transportation, business fares will apply. 

 

	 	b.	Use of Consultant vehicle will be compensated at €0,3461 per kilometre. This does not apply to Belgium, where the use of CONSULTANT vehicle will not be compensated. 

 

	 	7.	CONSULTANT will provide C3BS, not later than ten (10) working days after month end, with an invoice, including actual monthly fees calculation and actual variable expenses incurred during the previous month. All
variable expenses will be supported by appropriate invoices or receipts, as appropriate. C3BS shall initiate payment immediately upon receipt of physical invoice and in all cases not later than thirty (30) working days. C3BS can withhold the
total payment of the invoice in the case a part of the invoice is unclear or needs further investigation. C3BS shall notify CONSULTANT not later than 5 days upon receipt of an unclear invoice by e-mail to Director Finance giving details of the
information requiring clarification. 

  

	 	8.	All expenses higher than 500€ (Five hundred Euro) are subject to prior approval by the head of department concerned within C3BS. 

 

	 	9.	In addition to the amounts described above, C3BS shall reimburse CONSULTANT for its actual direct and documented costs in carrying out its obligations pursuant to this Agreement. 

  
 Page 10 of 10EX-10.9

 Exhibit 10.9 

CELDARA MEDICAL - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT 

This Agreement, effective this 30th day of April 2010, between 

TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire, and
being located at Hanover, New Hampshire 03755, hereinafter called Dartmouth, 
 and 

CELDARA MEDICAL, LLC., a company of the State of Delaware, with a principal place of business at 16 Cavendish Court, Centerra Resource Park,
DRTC, Lebanon, NH 03766; hereinafter called Company. 
 WHEREAS, Dartmouth, under the direction of principal investigator Charles
Sentman, Ph.D. has developed chimeric NKG2D receptor-based T cell therapies including TCR-less T cells expressing targeting receptor(s) known as the Art; and 

WHEREAS, Dartmouth represents that it has the right to grant licenses granted in this agreement; and 

WHEREAS, Company wishes to obtain a license under the terms and conditions hereinafter set forth, and to use its expertise and resources to
practice and market the technology; 
 NOW THEREFORE, in consideration of the premises and the faithful performance of the covenants herein
contained, IT IS AGREED: 
 ARTICLE I. Definitions 

Section 1.01 Dartmouth Know-How. “Dartmouth Know-How” shall mean the ideas, methods, characterization and techniques
developed by Dr. Sentman at Dartmouth before the Effective Date, which are necessary for practicing Dartmouth Patent Rights. 

Section 1.02 Dartmouth Patent Rights. “Dartmouth Patent Rights” shall mean United States Patent Application Serial No.:
11/575,878, filed April 19, 2007, United States Patent Application Serial No.: 12/407,440, filed March 19, 2009, and United States Provisional Application Serial No.: 61/255,980, filed October 29, 2009, and any applications which
claim benefit of priority to said Patent Applications, and any United States or Foreign Patents issuing therefrom, and any continuations, continuations-in-part, divisions, reissues, reexaminations or extensions thereof. Dartmouth shall be the
assignee and owner of all such Patents and Patent Applications. 

  
 pg. 1 

 Section 1.03 Licensed Products. “Licensed Products” shall mean any products
or processes covered by or made, in whole or in part, by the use of Dartmouth Patent Rights or by the use of Dartmouth Know-How. 

Section 1.04 Field. The “Field” of this Agreement shall mean the Art. 

Section 1.05 Territory. The “Territory” shall mean worldwide. 

Section 1.06 Subsidiary. “Subsidiary” shall mean a legal entity at least 50% of the voting stock of which is owned
directly or indirectly by Company. 
 Section 1.07 Agreement. “Agreement” shall mean this License Agreement. 

Section 1.08 Net Sales. “Net Sales” shall mean the gross billing price Company, its subsidiaries and sublicensees charge
to their customers for Licensed Products, less sales, use, occupation and excise taxes, and transportation, discounts, returns and allowances in lieu of returns. 

Section 1.09 Effective Date. “Effective Date” shall mean the date first written above and shall be the Effective Date of
this Agreement. 
 Section 1.10 License Year. The “First License Year” shall mean the period commencing on the
Effective Date and ending December 31, 2010. The second and all subsequent “License Years” shall commence on January 1 and end on December 31 of each year. 

Section 1.11 Calendar Quarter. “Calendar Quarter” shall mean the periods ending on
March 31, June 30, September 30 and December 31 of each year. 
 ARTICLE II. Grant 

Section 2.01 License Grant. Dartmouth hereby grants to Company and its Subsidiaries an exclusive, royalty-bearing license under
Dartmouth Know-How and Dartmouth Patent Rights to make, have made, use, and/or sell Licensed Products in the Field in the Territory. Notwithstanding the foregoing, Dartmouth expressly reserves a non-transferable royalty-free right to use the
Dartmouth Patent Rights and Dartmouth Know-How in the Field itself, including use by its faculty, staff and researchers, for educational and research purposes only. Company agrees during the period of exclusivity of this license in the United States
that any Licensed Product produced for sale in the United States will be manufactured substantially in the United States. 

  
 pg. 2 

 Section 2.02 Sublicenses. Company shall have the right to grant sublicenses to third
parties under Dartmouth Know-How and Patent Rights to make, have made, use and sell the Licensed Products with the consent of Dartmouth, which consent shall not be unreasonably withheld, except that such sublicenses shall be in writing and expressly
subject to the terms of this Agreement. Company agrees to be responsible for the performance hereunder by its sublicensees. Dartmouth shall have the right to review such sublicenses to assure conformity with this Section. Upon termination of this
Agreement, any such sublicenses will revert directly to Dartmouth. 
 Section 2.03 Patents. Company shall reimburse Dartmouth
for all expenses ($32,820.28) Dartmouth has incurred for the preparation, filing, prosecution and maintenance of Dartmouth Patent Rights as of the Effective Date within thirty (30) days of Company’s receipt of a detailed invoice. Company
shall engage patent attorney(s) acceptable to Dartmouth (“Firm”). Company shall be responsible for future expenses in connection with preparation, filing, prosecution and maintenance of Dartmouth Patent Rights. 

Dartmouth, Company and the Firm shall interact as described in the Client and Billing Agreement (Attachment A). If Company chooses to discontinue prosecution
or maintenance of any United States Patent or Patent Application, which is a subject of Dartmouth Patent Rights, it will so inform Dartmouth within a reasonable time before implementation of such decision. Dartmouth then shall have the right to
prosecute or maintain such Patent or Patent Application on its own and at its own expense, in which case the license to Company under such Patent or Patent Application will terminate. COMPANY shall notify Dartmouth by at least three (3) months
before a National Phase deadline whether it will support the filing of patent applications in particular foreign territories. If COMPANY decides not to support the filing or maintaining foreign applications, Dartmouth reserves the right to file or
maintain such applications on its own, in which case the license to COMPANY in the particular territory will terminate. 
 ARTICLE III.
 
 Disclosure of Invention, Confidentiality and Representations 

Section 3.01 Disclosure of Invention. Dartmouth agrees promptly after the Effective Date of this Agreement to deliver and to
disclose to duly authorized representatives of Company, all proprietary technical data, methods, processes, including the technology, and other information and specifications relating to Dartmouth Know-How. 

  
 pg. 3 

 Section 3.02 Mutual Confidentiality. Company and Dartmouth realize that some
information received by one party from the other pursuant to this Agreement shall be confidential. It is therefore agreed that any information received by one party from the other, and clearly designated in writing as “CONFIDENTIAL”
at the time of transfer, shall not be disclosed by either party to any third party and shall not be used by either party for purposes other than those contemplated by this Agreement for a period of three (3) years from the termination of the
Agreement, unless or until — 
 (a) said information shall become known to third parties not under any obligation of confidentiality to
the disclosing party, or shall become publicly known through no fault of the receiving party, or 
 (b) said information was already in the
receiving party’s possession prior to the disclosure of said information to the receiving party, except in cases when the information has been covered by a preexisting Confidentiality Agreement, or 

(c) said information shall be subsequently disclosed to the receiving party by a third party not under any obligation of confidentiality to the
disclosing party, or 
 (d) said information is approved for disclosure by prior written consent of the disclosing party, or 

(e) said information is required to be disclosed by court order or governmental law or regulation, provided that the receiving party gives the
disclosing party prompt notice of any such requirement and cooperates with the disclosing party in attempting to limit such disclosure. 

Section 3.03 Corporate Action. Dartmouth and Company each represent and warrant to the other party that they have full power and
authority to enter into this Agreement and carry out the transactions contemplated hereby, and that all necessary corporate action had been duly taken in this regard. 

ARTICLE IV. Due Diligence 

Section 4.01 Milestones. Company has represented to Dartmouth, to induce Dartmouth to issue this license, that it will commit
itself to a diligent program of exploiting the Licensed Products so that public utilization will result therefrom. As evidence thereof, Company shall adhere to the following milestones: 

 

			
	 Filing of IND
		2 years from the Effective Date
	 Enrollment of first patient into Phase I clinical trial
		8 months after IND filing
	 Enrollment of first patient into Phase II clinical trial
		2 years from start of Phase I
	 Enrollment of first patient into Phase III clinical trial
		2 years from start of Phase II
	 Filing NDA
		1 year after the end of Phase III
	 FDA approval
		2 years from NDA filing

  
 pg. 4 

 Section 4.02 Minimum Net Sales. After fourteen (14) years from the Effective
Date of this Agreement, Dartmouth shall have the right, upon thirty (30) days written notice, to terminate the license, if Company fails, either by itself or through its Subsidiaries or Sublicensees, to market sufficient quantities of Licensed
Products to provide, in each of the following years, a total minimum Net Sales of at least: 
 (a) $10,000,000 during the first year of
Sales; 
 (b) $40,000,000 during the second year of Sales; 

(c) $100,000,000 during the third year of Sales and every year of sales thereafter. 

Section 4.03 Minimum Royalty. If Company has failed to meet the minimum Net Sales amounts set forth in Section 4.02 of the
Agreement in any one year and Dartmouth has provided thirty (30) days notice to Company that it intends to terminate the license granted hereunder, Company shall have the right to maintain the license by paying Dartmouth within such thirty
(30) day period the royalty it would otherwise be obligated to pay under this Agreement if it had met the Minimum Net Sales amount. 

ARTICLE V. Payments, Records and Reports 

Section 5.01 Payments. For the rights and privileges granted under this license, Company shall pay to Dartmouth 

(a) an earned royalty of 3% based on the value of Net Sales of the Licensed Products; and 

(b) annual license maintenance fee of $20,000 due upon each anniversary of the Agreement; and 

(c) following percentages of any consideration, received from an infringement settlement, less litigation expenditures, as described in
Section 8.01, and from each sublicense, except earned royalty on the sale of Licensed Products (e.g., license issue fees, license maintenance fees, etc.) received from each sublicensee of Company for the grant of a sublicense: 

50% if sublicense is granted during the preclinical stage of the product development up to the filing of an Investigational New Drug (IND) application; 

40% if sublicense is granted after the filing of an IND and prior to completion of Phase I Clinical Trial; 

30% if sublicense is granted after the completion of Phase I and before completion of Phase II Clinical Trial; 

  
 pg. 5 

 20% if the sublicense is granted after the completion of Phase II Clinical Trial and thereafter. 

Dartmouth acknowledges that Company’s business model includes the spin-off of companies, specifically including the formation of a new legal entity and
the transfer of some portion of Company’s assets to the new entity, which may include a sublicense, in which case this provision will not apply. 
 (e)
non-refundable, non-creditable milestone as follows: 
  

					
	 Filing of IND
		$	25,000	  
	 Enrollment of first patient into Phase I clinical trial
		$	75,000	  
	 Enrollment of first patient into Phase II clinical trial
		$	250,000	  
	 Enrollment of first patient into Phase III clinical trial
		$	250,000	  
	 Filing NDA
		$	400,000	  
	 FDA approval
		$	500,000	  

 It is acknowledged that if the above milestones are not accomplished by the dates specified in Section 4.01, the licenses
may be terminated unless payments in the above amounts are made to Dartmouth within thirty (30) days of the dates specified in Section 4.01. 

Section 5.02 Reports. Company shall render to Dartmouth upon request: 

(a) within thirty (30) days after the end of each Calendar Quarter a written account of all quantities of Licensed Products subject to
royalty hereunder sold by Company, any Subsidiary, and any sublicensee during such Calendar Quarter, the calculation of royalty thereon, and sufficient data for Dartmouth to verify the calculation, including gross sales and allowable deductions to
derive to Net Sales figures, and shall simultaneously pay in United States dollars to Dartmouth the royalty due with respect to such sales. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United
States on the date of royalty payments by Company. Such report shall be certified as correct by an officer of Company. If no Licensed Products subject to royalty hereunder have been sold by Company, its Subsidiaries and its sublicensees during any
such quarter, Company shall so report in writing to Dartmouth within thirty (30) days after the end of said quarter. If royalties for any License Year do not equal or exceed the minimum royalties established in Section 4.03, Company shall
include the balance of the minimum royalty with the payment for the Calendar Quarter ending December 31. Late payments shall be subject to an interest charge of one and one half percent (11/2%) per month. 

(b) within sixty (60) days after the close of each License Year written annual reports which shall include but not limited to: reports of
progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during preceding twelve (12) months as well as plans for coming year. Company shall also provide any reasonable additional data
Dartmouth requires to evaluate Company’s performance. 

  
 pg. 6 

 (c) within thirty (30) days of occurrence report of the date of first sale of Licensed
Products in each country. 
 Section 5.03 Books of Accounts. Company, its Subsidiaries and sublicensees shall keep full, true
and accurate books of accounts and other records containing all particulars which may be necessary for the purpose of ascertaining and verifying the royalties payable to Dartmouth by Company hereunder. Upon Dartmouth’s request, Company, its
Subsidiaries and sublicensees shall permit an independent Certified Accountant selected by Dartmouth (except one to whom Company has some reasonable objection), to periodically have access during ordinary business hours to such records of Company,
its Subsidiaries and sublicensees as may be necessary to determine, for any quarter ending not more than three (3) years prior to the date of such request, the correctness of any report and/or payment made under this Agreement. In the event
that any such inspection shows an underreporting and underpayment in excess of five percent (5%) for any twelve (12) month period, then Company shall pay the cost of such examination. 

ARTICLE VI. Technical Assistance and Commercial Development 

Section 6.01 Technical Assistance. Throughout the term of the Agreement, Dartmouth agrees to permit Company and its designees to
consult with its employees and agents regarding developments and enhancements made subsequent to the Effective Date relating to the Licensed Products, at such times and places as may be mutually agreed upon; provided that Company agrees to make
suitable arrangements with, and to compensate the Dartmouth employees and agents for such consultation. 
 Section 6.02 Commercial
Development. During the term of this Agreement, Company agrees to use commercially reasonable efforts to effectively market Licensed Products. Such efforts may include sublicensing, development of promotional literature, mailings, and journal
advertisements. 
 Section 6.03 Name. Neither party shall use nor permit to be used by any other person or entity the name of
the other party nor any adaptation thereof, or the name of either party’s employees not named in this agreement, in any advertising, promotional or sales literature, or for any other purpose without prior written permission of the other party,
except that Company may state that it is licensed by Dartmouth under Dartmouth Know-How and Patent Rights, and Dartmouth may state that it has licensed to Celdara Medical. 

  
 pg. 7 

 ARTICLE VII. Indemnity, Insurance, Disclaimers 

Section 7.01 Indemnity. Company shall defend and indemnify and hold Dartmouth and its trustees, officers, agents and employees
(the “Indemnitees”) harmless from any judgements and other liabilities based upon claims or causes of action against Dartmouth or its employees which arise out of alleged negligence in the development, manufacture or sale of Licensed
Products by Company, its Subsidiaries, and sublicensees, or from the use by the end users of Licensed Products, except to the extent that such judgements or liabilities arise in whole or in part from the gross negligence or willful misconduct of
Dartmouth or its employees, provided that Dartmouth promptly notifies Company of any such claim coming to its attention and that it cooperates with Company in the defense of such claim. If any such claims or causes of action are made, Dartmouth
shall be defended by counsel to Company, subject to Dartmouth’s approval, which shall not be unreasonably withheld. Dartmouth reserves the right to be represented by its own counsel at its own expense. 

Section 7.02 Insurance. At such time as any product, process, service relating to, or developed pursuant to, this Agreement is
being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by Company or by a sublicensee, Subsidiary or agent of Company, Company shall at its sole cost and expense, procure and maintain comprehensive
general liability insurance in amounts not less than $2,000,000 per incident and naming the Indemnitees as additional insureds. Such comprehensive general liability insurance shall provide (i) product liability coverage and (ii) broad form
contractual liability coverage for Company’s indemnification under this Agreement. If Company elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of $250,000 annual aggregate)
such self-insurance program must be acceptable to Dartmouth and Dartmouth Risk Manager. Such insurance will be considered primary as to any other valid and collectible insurance, but only as to acts of the named insured. The minimum amounts of
insurance coverage required shall not be construed to create a limit of Company’s liability with respect to its indemnification under this Agreement. 

Company shall provide Dartmouth with written evidence of such insurance upon request of Dartmouth. Company shall provide Dartmouth with written notice at
least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if Company does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, Dartmouth shall have
the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 

  
 pg. 8 

 Company shall maintain such comprehensive general liability insurance beyond the expiration or termination of
this Agreement during (I) the period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially distributed or sold by Company or by a sublicensee, Subsidiary or agent of Company and
(ii) a reasonable period after the period referred to in (i) above which in no event shall be less than fifteen (15) years. 

Section 7.03 Disclaimer. Nothing contained in this Agreement shall be construed as: 

(a) a warranty or representation by Dartmouth as to the validity or scope of any Patent Rights; 

(b) a warranty or representation that any Licensed Products manufactured, used or sold will be free from infringement of patents, copyrights,
or rights of third parties, except that Dartmouth represents that it has no knowledge of any existing issued patents or copyrights which might be infringed; 

(c) except as provided in Section 7.01, an agreement to defend against actions or suits of any nature brought by any third parties. 

DARTMOUTH MAKES NO WARRANTIES, EXPRESS OR IMPLIED, AS TO THE 

MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF 

LICENSED PRODUCTS 

ARTICLE VIII. Infringement Matters 

Section 8.01 Infringement by Third Parties. Company shall give Dartmouth prompt notice of any incident of infringement of
Dartmouth Patent Rights coming to its attention. The parties shall thereupon confer together as to what steps are to be taken to stop or prevent such infringement. Dartmouth agrees to use reasonable efforts to stop any such infringement, but shall
not be obliged to commence proceedings against the infringer. If Dartmouth decides to commence proceedings however, Dartmouth shall be responsible for any legal costs incurred and will be entitled to retain any damages recovered. Should Dartmouth
decide not to commence proceedings, Company shall be entitled to do so in its own name against the infringer, in which event Company shall be responsible for all legal costs incurred, without recourse to Dartmouth. Financial recoveries from any such
litigation will first be applied to reimburse Company for its litigation expenditures with additional recoveries being paid to Company, subject to payments due Dartmouth per Sections 5.01 (a) and (c). In any action to enforce Dartmouth Patent
Rights, either party, at the request and expense of the other party shall cooperate to the fullest extent reasonably possible. 

  
 pg. 9 

 ARTICLE IX. Duration and Termination 

Section 9.01 Term. This Agreement shall become effective upon the date first written above, and unless sooner terminated in
accordance with any of the provisions herein, shall remain in full force during the life of the last to expire patents under Dartmouth Patent Rights contemplated by this agreement in the last to expire territory. If mutually desired, the parties may
negotiate for an extension of this License. Upon the termination of the Agreement Company shall have the right to sell the remainder of the Licensed Product on hand, provided the sales will be subject to the royalty payments of this Agreement. 

Section 9.02 Termination - Breach. In the event that either party defaults or breaches any of the provisions of this Agreement,
the other party shall have the right to terminate this Agreement by giving written notice to the defaulting party, provided, however, that if the said defaulting party cures said default within thirty (30) days after said notice shall have been
given, this Agreement shall continue in full force and effect. The failure on the part of either of the parties hereto to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver of any such right nor operate to
bar the exercise or enforcement thereof at any time or times thereafter. 
 Section 9.03 Insolvency. In the event that Company
shall become insolvent, shall make an assignment for the benefit of creditors, or shall have a petition in bankruptcy filed for or against it, the Agreement shall terminate. 

Section 9.04 Prior Obligations and Survivability. Termination of this Agreement for any reason shall not release either party from
any obligation theretofore accrued. Sections 3.02, 5.01 – 5.03, 7.01 – 7.03, 10.01 – 10.09 shall survive the termination of this Agreement. 

ARTICLE X. Miscellaneous 

Section 10.01 Governing Law. This Agreement shall be construed, governed, interpreted and enforced according to the laws of the
State of New Hampshire. 
 Section 10.02 Notices. Any notice or communication required or permitted to be given by either party
hereunder, shall be deemed sufficiently given, if mailed by certified mail, return receipt requested, and addressed to the party to whom notice is given as follows: 
  

			
	If to Company, to:		
		
			 Jake Reder
 CEO

Celdara Medical, LLC.
 16 Cavendish Ct., Centerra Resource Park,
DRTC
 Lebanon, NH 03766

  
 pg. 10 

			
	If to Dartmouth, to:		
		
			 Alla Kan
 Director

Technology Transfer Office
 Dartmouth College

11 Rope Ferry Road
 Hanover, NH 03755

 Section 10.03. Assignment. Dartmouth acknowledges that Company’s business model includes the
spin-off of companies, specifically including the formation of a new legal entity and the transfer of some portion of Company’s assets to the new entity which may include Assignment of this Agreement. Beyond this exception, neither party shall
assign or transfer this Agreement without the express prior written consent of the other, which shall not be unreasonably withheld. For purposes of this Agreement, an assignment or transfer of this Agreement by COMPANY shall be deemed to occur in
connection with (a) an express assignment or transfer, (b) a general assignment for the benefit of creditors or in connection with any bankruptcy or other debtor relief law, (c) any merger or consolidation to which COMPANY is a party,
regardless of whether COMPANY is the surviving corporation, or (d) any other transaction pursuant to which a change would occur in the “ultimate parent entity” of COMPANY, applying the rules in effect from time to time under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 
 Section 10.04 Entire Agreement. This Agreement represents
the entire Agreement between the parties as of the effective date hereof, and may only be subsequently altered or modified by an instrument in writing. This agreement cancels and supersedes any and all prior oral or written agreements between the
parties which relate to the subject matter of this Agreement. 
 Section 10.05 Mediation and Arbitration. Both parties agree
that they shall attempt to resolve any dispute arising from this Agreement through mediation. Both parties agree that at least one employee, capable of negotiating an agreement on behalf of his employer, shall, within three weeks of receipt of
written notification of a dispute, meet with at least one employee of the other party who is also capable of negotiating an agreement on behalf of his employer. If no agreement can be reached, both parties agree to meet again within a four week
period after the initial meeting to negotiate in good faith to resolve the dispute. If no agreement can be reached after this second meeting, both parties agree to submit the dispute to binding arbitration under the Rules of the American Arbitration
Association before a single arbitrator. 

  
 pg. 11 

 Section 10.06 Waiver. A failure by one of the parties to this Agreement to assert its
rights for or upon any breach or default of this Agreement shall not be deemed a waiver of such rights nor shall any such waiver be implied from acceptance of any payment. No such failure or waiver in writing by any one of the parties hereto with
respect to any rights, shall extend to or affect any subsequent breach or impair any right consequent thereon. 
 Section 10.07
Severability. The parties agree that it is the intention of neither party to violate any public policy, statutory or common laws, and governmental or supranational regulations; that if any sentence, paragraph, clause or combination of the
same is in violation of any applicable law or regulation, or is unenforceable or void for any reason whatsoever, such sentence, paragraph, clause or combinations of the same shall be inoperative and the remainder of the Agreement shall remain
binding upon the parties. 
 Section 10.08 Marking. Company agrees to mark the Licensed Products with all applicable trademarks,
and patent numbers. 
 Section 10.09 Headings. The headings of the paragraphs of this Agreement are inserted for convenience
only and shall not constitute a part hereof. 

  
 pg. 12 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement, in duplicate originals, by
their respective officers hereunto duly authorized, the day and year herein written. 
  

			
	THE TRUSTEES OF DARTMOUTH COLLEGE
		
	        By		/s/ Alla Kan
		
	        Date		May 5, 2010
		
	        Name		Alla Kan, Director
	        Title		Technology Transfer Office
	
	CELDARA MEDICAL, LLC
		
	        By		/s/ Jake Reder
		
	        Date		April 30, 2010
		
	        Name		Jake Reder
	        Title		CEO

  
 pg. 13 

 Attachment A: Client and Billing Agreement 

Reference Doc: Procedures to be Followed by Hunton & Williams LLP in Regard to Licensed Dartmouth Patent Rights 

  
 pg. 14 

 FIRST AMENDMENT TO 

CELDARA - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT 

THIS FIRST AMENDMENT (“Amendment”) is effective as of February 20, 2012, by and between the TRUSTEES OF DARTMOUTH
COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire (hereinafter “Dartmouth”) and Celdara Medical, LLC having its principal place of business at 16 Cavendish Court,
Centerra Resource Park, DRTC, Lebanon, NH 03766 (hereinafter “Celdara”). 
 WHEREAS, the parties previously entered into an
Exclusive License Agreement, dated April 30, 2010 (the “Agreement”); and 
 WHEREAS, the parties desire to amend said
Agreement as set forth herein; 
 NOW, THEREFORE, in consideration of the premises and the covenants herein contained, the parties
hereby agree to amend the Agreement as follows: 
 Following language shall be added to Section 1.02 Dartmouth Patent Rights:
“Dartmouth Patent Rights” shall also include Dartmouth’s Rights under Provisional Patent Application Serial No. 61/529,410 filed August 31, 2011 and Dartmouth’s rights, under any applications which claim benefit of
priority to said Provisional Patent Application, and any United States or Foreign Patents issuing therefrom, and any continuations, continuations-in-part, divisions, reissues, reexaminations or extensions thereof. 

All other terms and conditions of the Agreement shall remain in full force and effect. 

IN WITNESS WHEREOF, the parties have duly executed this Amendment in duplicate originals, by their respective officers hereunto duly authorized, as of
the date herein written. 
  

							
	CELDARA MEDICAL, LLC		TRUSTEES OF DARTMOUTH COLLEGE
				
	By:		/s/ Jake Reder		By:		/s/ Alla Kan
	Name:		Jake Reder		Name:		Alla Kan, Director
	Title:		CEO		Title:		Technology Transfer Office
	Date:		Mar 23, 12		Date:		2/21/12

  

 SECOND AMENDMENT TO 

CELDARA - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT 

THIS SECOND AMENDMENT (“Amendment”) is effective as of July 26, 2013, by and between the TRUSTEES OF DARTMOUTH
COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire (hereinafter “Dartmouth”) and Celdara Medical, LLC having its principal place of business at 16 Cavendish Court,
Centerra Resource Park, DRTC, Lebanon, NH 03766 (hereinafter “Celdara”). 
 WHEREAS, the parties previously entered into an
Exclusive License Agreement, dated April 30, 2010, amended on February 20, 2012 (the “Agreement”); and 

WHEREAS, the parties desire to amend said Agreement as set forth herein; 

NOW, THEREFORE, in consideration of the premises and the covenants herein contained, the parties hereby agree to amend the Agreement as
follows: 
 Delete Section 10.03 in its entirety and substitute with the following: 

“Section 10.03. Assignment. Dartmouth acknowledges that Company’s business model includes the spin-off of companies, specifically including
the formation of a new legal entity and the transfer of some portion of Company’s assets to the new entity which may include Assignment of this Agreement. Beyond this exception, Dartmouth shall have the right to review a transaction involving
assignment or transfer of this Agreement. Parties agree to abide by the terms of this Agreement, as they pertain to such transaction. For purposes of this Agreement, an assignment or transfer of this Agreement by COMPANY shall be deemed to occur in
connection with (a) an express assignment or transfer, (b) a general assignment for the benefit of creditors or in connection with any bankruptcy or other debtor relief law, (c) any merger or consolidation to which COMPANY is a party,
regardless of whether COMPANY is the surviving corporation, or (d) any other transaction pursuant to which a change would occur in the “ultimate parent entity” of COMPANY, applying the rules in effect from time to time under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.” 
 All other terms and conditions of the Agreement shall remain in
full force and effect. 
 IN WITNESS WHEREOF, the parties have duly executed this Amendment in duplicate originals, by their respective officers
hereunto duly authorized, as of the date herein written. 
  

									
	CELDARA MEDICAL, LLC				TRUSTEES OF DARTMOUTH COLLEGE
					
	By:		 /s/ Jake Reder
				By:		 /s/ Alla Kan

	Name:		Jake Reder				Name:		Alla Kan, Director
	Title:		CEO				Title:		Technology Transfer Office
	Date:		Aug 14, 13				Date:		7/26/13

  

 THIRD AMENDMENT TO 

CELDARA - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT 

THIS THIRD AMENDMENT (the “Third Amendment”) is effective as of January 4, 2015, by and between the TRUSTEES OF
DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire (hereinafter “Dartmouth”) and Celdara Medical, LLC having its principal place of business at 16
Cavendish Court, Centerra Resource Park, DRTC, Lebanon, NH 03766 (hereinafter “Celdara”). 
 WHEREAS, the parties
previously entered into an Exclusive License Agreement, dated April 30, 2010 amended on February 20, 2012 and amended again on July 26, 2013 the “Agreement”) (capitalized terms used but not otherwise defined in this Third
Amendment shall have the meanings given such terms in the Agreement); 
 WHEREAS, the parties wish to amend the Agreement in
the manner set forth in this Third Amendment and otherwise to provide for certain agreements by the parties as set forth herein; 
 NOW,
THEREFORE, in consideration of the premises and the covenants herein contained, the parties hereby agree to amend the Agreement as follows: 

1. Section 1.03 is hereby amended and restated in its entirety as follows: 

“Section 1.03 Licensed Products. “Licensed Products” shall mean any product or process, the manufacture, use or sale of
which, in whole or in part, is covered by the Dartmouth Patent Rights.” 
 2. Section 1.04 is hereby amended and restated in
its entirety as follows: 
 “Section 1.04 Field. The “Field” of this Agreement shall mean human
therapeutics.” 
 3. Section 5.01(a) is hereby amended and restated in its entirety as follows: 

“(a) an earned royalty of 2% based on the value of Net Sales of the Licensed Products; and” 

4. Section 5.01(c) is hereby amended and restated in its entirety as follows: 

“(c) following percentages of any consideration received by the Company from an infringement settlement, less litigation expenditures, as
described in Section 8.01, or received by the Company from each sublicensee of the Company for the grant of a sublicense hereunder with respect to any Licensed Products (e.g. license issue fees, license maintenance fees, etc.), except earned
royalty on the sale of any Licensed Products: 

  
 1 

 (i) 15% if such sublicense is granted by the Company during the preclinical development stage of
such Licensed Product up to administration of the first dose in a Phase I clinical trial for such Licensed Product; 
 (ii) 10% if such
sublicense is granted by the Company after the administration of the first dose in a Phase I clinical trial for such Licensed Product and prior to completion of a Phase II clinical trial for such Licensed Product; or 

(iii) 5% if such sublicense is granted by the Company after the completion of a Phase II clinical trial for such Licensed Product and
thereafter.” 
 5. Section 6.02 is hereby amended and restated in its entirety as follows: 

“Section 6.02 Commercial Development. During the term of this Agreement, the Company will use commercially reasonable efforts to
achieve the milestone targets set forth herein. These efforts will include use of commercially reasonable efforts to develop and commercialize Licensed Products. Company will use commercially reasonable efforts to maintain or cause to be maintained
by the Company a bona fide, fully funded, fully staffed ongoing and active research, development, manufacturing, regulatory, business development, marketing and sales effort to make the Licensed Products commercially available as soon as
commercially practicable.” 
 6. Except as specifically amended by this Third Amendment, the terms and conditions of the Agreement
shall remain in full force and effect. 
 7. This Third Amendment shall be construed, governed, interpreted and enforced according to the
laws of the State of New Hampshire. 
 8. This Third Amendment may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Third Amendment by facsimile or by email of a scanned copy will be effective as delivery of an original
executed counterpart of this Third Amendment. 

  
 2 

 IN WITNESS WHEREOF, the parties have duly executed this Third Amendment in duplicate originals, by their
respective officers hereunto duly authorized, as of the date herein written. 
  

									
	CELDARA MEDICAL, LLC				TRUSTEES OF DARTMOUTH COLLEGE
					
	By:		 /s/ Jake Reder
				By:		 /s/ Glennis Gold

	Name:		Jake Reder, Ph.D.				Name:		Glennis Gold, Interim Director
	Title:		CEO				Title:		Technology Transfer Office

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]